“Insights into the development progress and clinical evaluation of the candidate malaria vaccine R21/Matrix-M”
Monday 25/4/2021, 2 – 3 pm
Register in advance via Zoom.
Malaria causes more than 400,000 deaths a year globally, according to the World Health Organization (WHO), mostly among children in Sub-Saharan Africa. In the fight against the disease, the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso, one of ITM’s longstanding partner institutions, is developing the R21/Matrix-M vaccine, in collaboration with their partners at the University of Oxford in the UK. Preliminary results show that this is the first malaria vaccine to reach the 75 per cent efficacy target set by the WHO, a promising breakthrough in the fight against malaria.
In light of World Malaria Day, ITM PhD alumnus and CRUN-researcher Dr H. Magloire Natama, will share the research findings and results of the development and clinical evaluation of the vaccine candidate R21/Matrix-M, currently in the last testing phase. As coordinator of the clinical trial of the vaccine in Nanoro, he will also outline the next steps in the development process as well as the perspectives in terms of manufacturing and supply of the vaccine.
The Q&A-session will be moderated by Dr Ula Maniewski-Kelner, internal medicine physician and infectiologist specialized in travel medicine and tropical medicine, working at the ITM Travel Clinic.
- H. Magloire Natama, Researcher and coordinator clinical trial R21/Matrix-M @Clinical Research Unit of Nanoro (CRUN), Burkina Faso
- Ula Maniewski-Kelner, Internal medicine physician and infectiologist @Travel Clinic, ITM, Antwerp
Thanks for sharing the information within your networks!